The effects of sleep disturbance, race, sex, and age on Hoehn Yahr scores in Parkinson's disease patients: a cross-sectional study by Bayers, Christopher
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
The effects of sleep disturbance,
race, sex, and age on Hoehn Yahr
scores in Parkinson's disease
patients: a cross-sectional study
https://hdl.handle.net/2144/16801
Boston University
	 	 	
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
THE EFFECTS OF SLEEP DISTURBANCE, RACE, SEX, AND AGE ON 
HOEHN YAHR SCORES IN PARKINSON’S PATIENTS: A CROSS-
SECTIONAL STUDY 
 
 
 
 
by 
 
 
 
 
CHRISTOPHER SEAN BAYERS 
 
B.S., Fordham University, 2013 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2016  
	 	 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2016 by 
 CHRISTOPHER SEAN BAYERS 
 All rights reserved  
	 	 	
Approved by 
 
 
 
 
First Reader   
 Fernando Garcia-Diaz, Ph.D. 
 Associate Professor of Physiology and Biophysics 
 Boston University, School of Medicine 
 
 
Second Reader   
 Anna Hohler, MD. 
 Associate Professor of Neurology  
 Boston University, School of Medicine 
 
 
Third Reader   
 Stacey Hess Pino, MS, MS. 
 Assistant Director, MS in Clinical Investigation Program   
 Boston University, School of Medicine 
 
 
		 iv 
DEDICATION 
 
 
 
 
I would like to dedicate this work to my grandfather Silvio Drinkwater. Silvio struggled 
with Parkinson’s disease for ten years, which sparked my interest in Parkinson’s research. 
Hopefully though the intense study of Parkinson’s disease better treatments will become 
available to help patients in the future.  
  
		 v 
ACKNOWLEDGMENTS 
 
I would like to thank my committee members for their support and guidance through the 
thesis process, as well as for their assistance with editing. I would also like to thank 
Emily Bowman for her support and editing assistance.   
		 vi 
THE EFFECTS OF SLEEP DISTURBANCE, RACE, SEX AND AGE ON HOEHN 
YAHR SCORES IN PARKINSON’S PATIENTS: A CROSS-SECTIONAL STUDY 
CHRISTOPHER SEAN BAYERS 
ABSTRACT 
 The objective of this study was to determine the effects race, sex and sleep 
disturbance have on the severity of Parkinson’s disease as assessed by the Hoehn Yahr 
(HY) score in both the medicated (ON) and non-medicated (OFF) states. The potentially 
confounding variables of age, time in years from the onset of symptoms to database 
entry, and education were taken into account. Secondary analysis was also conducted to 
determine how the non-motor symptoms of dementia, hallucinations and autonomic 
dysfunction impacted Hoehn Yahr ON and OFF scores.  
 This study used the statistical techniques of the Student’s t-test, ANOVA, Tukey-
Kramer test, univariate linear regression, and multivariate regression. The t-tests and 
ANOVA test revealed that there was no significant differences in mean HY ON and OFF 
scores between the sexes, patients with and without sleep disturbance, and between the 
different races analyzed in this study. Patients with and without sleep disturbance did 
show significantly higher HY ON scores as compared to HY OFF scores, which is 
peculiar as this finding suggests that these patients are not responding to their medication.  
The univariate linear regression models did show, however, that time in years 
from the onset of symptoms to database entry did significantly impact both HY ON and 
OFF scores, whereas age is only shown to have a significant impact on HY OFF scores. 
Additionally, the univariate linear regression model analyzing the association between 
		 vii 
education and HY OFF scores showed that having some high school education, but not 
receiving a degree, was associated with an increase in HY OFF scores.  
 Several multivariate linear regression models where built to assess the impact 
different predictor variables had on HY ON and HY OFF scores. The first two 
multivariate models used the predictor variables of age, race, and time in years from the 
onset of symptoms until database entry. These models showed that only time in years 
from the onset of symptoms until database entry impacted HY ON scores, whereas all 
three of these predictor variables impacted HY OFF scores. Two additional multivariate 
linear regression models were built to assess how age, race, time in years from the onset 
of symptoms until database entry, dementia, autonomic dysfunction and hallucinations all 
impacted HY ON and OFF scores. These models revealed that all of these predictors, 
when taken together, significantly impacted HY OFF scores, but not HY ON scores.  
 Finally a scatter plot was made comparing HY ON and HY OFF scores. A 
LOWESS scatter plot smooth line was also superimposed on top of this plot to show the 
overall trend these scores had on one another. This scatter plot was interesting because it 
suggested that there were two spate groups of patients contained in this database, those 
that responded well to medication and those that did not.  
 Overall, this study showed that age, time in years from the onset of symptoms 
until database entry, education and race impacted HY OFF scores. Furthermore, the 
analysis indicated that patients who were asked about sleep disturbance did not appear to 
be responding to medication. There are several limitations to this study, however, with 
the most important being missing data and the cross-sectional design. Missing data 
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prevented sleep disturbance from being thoroughly analyzed and the cross-sectional 
design does not allow for any causal relationships to be determined. 
  
		 ix 
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INTRODUCTION 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that 
primarily affects the dopaminergic system in the brain.1,2 Parkinson’s disease was first 
described in 1817 by James Parkinson in his paper titled An Essay on Shaking Palsy.2,3 
French neurologist Jean-Martin Charcot was the first to advocate for the use of the term 
Parkinson’s disease over shaking palsy because Charcot observed that PD patients did not 
always present with the symptom of a resting tremor and did not have muscle weakness.3  
 
PD is the second most common neurodegenerative disease1, the most common movement 
disorder4, and was ranked as the 14th most common cause of death in the United States in 
2010.5 PD is estimated to effect more than 500,000 people currently, with 50,000 new 
cases reported annually.1 PD usually effects patients who are 60-years of age or older1, 
but PD has been seen in younger patients as 10% of PD cases develop before the age of 
50.2  
 
The costs associated with PD are significant in the United States. In 2010 the estimated 
cost incurred by each PD patient on Medicare was 10,387 dollars.6 The annual cost of PD 
is estimated to be around 25 billion dollars annually7, which will only increase as the 
current population ages.  
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Pathophysiology/Staging  
The main macroscopic change seen in the brain of PD patients is the loss of 
neuromelanin-containing neurons in the substantia nigra pars compacta (SNpc).2,8 
Neuromelanin is a dark pigment that causes the SN to have a black appearance, which is 
where its name substantia nigra, Latin for ‘black substance’, originates.8 In addition to the 
SN, neuronal degeneration also occurs in the locus ceruleus (LC), the dorsal motor 
nucleus of the vagus (DMN), and the basal nucleus of Meynert (nbM).2,8 The loss of 
pigment, which accumulates with age in the SN and LC, is indicative of neuronal loss.8 
Lewy bodies (see below) are also a pathological hallmark of PD.2,8 Furthermore, the 
brains of PD patients might also exhibit enlarged ventricles, particularly in the frontal 
horns, as well as mild atrophy of the frontal lobe. Otherwise the brains of PD patients 
appear to be normal, which can help to distinguish progressive supranuclear palsy (PSP) 
and multiple systems atrophy (MSA) from PD. PSP exhibits atrophy of the midbrain and 
MSA exhibits atrophy of the pontine nucleus of the basal ganglia.8  
 
Microscopically, PD patients have Lewy bodies (LBs) as well as neuritic processes 
throughout the SN, LC, DMN and nbM.8 LBs are eosinophilic intracytoplamsmic 
globular granular inclusions that are composed of 𝛼-synuclein and ubiquitin.8 𝛼-
synuclein is normally found at the presynaptic terminals of neurons and it is still 
unknown how 𝛼-synuclein becomes deformed and accumulates in the cytoplasm of 
neurons to form LBs.8 There are two different types of neuritic process that occur within 
the brains of PD patients: those that stain with hematoxylin and eosin, referred to as 
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intraneuritic LBs, and those that remain invisible on routine histological examination, 
referred to as Lewy neurites (LNs).8 LNs are frequently seen in the amygdala, 
hippocampus and neocortex.8  
 
Many of the motor symptoms experienced by PD patients are accounted for by 
degeneration of the basal ganglia. The basal ganglia is composed of the following: the 
dorsal striatum, that contains the caudate nucleus and the putamen; the external globus 
pallidus (GPe); the internal globus pallidus (GPi); the substantia nigra (SN), that is made 
up of the pars compacta (SNpc) with dopaminergic neurons and the pars reticulata (SNpr) 
with GABAergic neurons; and the subthalamic nucleus (STN).8  
 
There are two major pathways within the basal ganglia that control motor movements by 
modulating the activity of the thalamus; the direct and indirect pathways.9,10 These two 
pathways work in a reciprocal fashion with the direct pathway stimulating the thalamus 
resulting in increased movement, and the indirect pathway decreasing activity within the 
thalamus, thereby reducing movement.9  
 
The direct pathway functions in the following way: Excitatory glutiminergic neurons 
project from the cortex to the striatium and to the STN, stimulating their excitation.9 The 
striatum sends inhibitory 𝛾-aminobutyric acid (GABA) –ergic neurons to the GPi2, which 
also sends GABAergic neurons to the thalamus resulting in its inhibition.9 The thalamus 
sends glutiminergic projections to the motor cortex resulting in its excitation.9 This 
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pathway ultimately leads to a decreased inhibition of the thalamus allowing it to send 
more excitatory signals to the motor cortex, thereby stimulating more movement.10 The 
STN helps to modulate the amount of movement produced in the direct pathway by 
exciting the SNpc, which sends excitatory dopaminergic neurons to the striatum.9,10 
Dopamine then binds to D1 receptors9 on the inhibitory neurons of the striatum leading to 
further inhibition of the GPi. Consequently, the thalamus is less inhibited, producing 
more movement.2,8,9 When the SN becomes over-stimulated the SNpr sends GABA to the 
STN via GABAminergic neurons, thereby inhibiting the STN. The inhibition of the STN 
results in less excitation of the SNpc, ultimately leading to more inhibition of the 
thalamus and deceased movement.8–10  
 
The indirect pathway is composed of GABAergic striatal neurons that project to the 
GPe.9 The GPe has GABAergic neurons that project to the STN, which has glutamatergic 
neurons that project to the GPi resulting in its excitation.2,9 Stimulation of the GPi results 
in increased inhibition of the thalamus causing decreased movement.8,9 The SNpc sends 
dopaminergic projections to the striatum, which binds to D2 receptors9 in the striatum 
causing the GABAergic projections of the striatum to be inhibited, leading to decreased 
inhibition of the thalamus and ultimately more movement.8,9 
 
Both the direct and indirect pathways reveal the key role that SN plays in modulating 
movement through the two distinct neuronal populations. The degradation of SN that 
occurs in PD patients ultimately results in the decreased activity of the direct pathway 
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and an increased activity of the indirect pathway.2,8–10 It is postulated that the increased 
inhibition of the thalamus from the indirect pathway is one of the primary means by 
which bradykinesia results in PD patients.2,9 This model does have some short comings as 
it cannot explain the observed reduction of bradykinesia and dyskinesia from a 
pallidotomy.2 Additionally, this model doesn’t explain the non-motor symptoms (NMS) 
that are also observed in PD.  
 
There is a model proposed by Braak that does account for some of the NMS that occur in 
PD. Braak and his team assumed that the pathology of PD develops in a predetermined 
manner through the brain before the clinical motor symptoms become apparent.11 From 
this assumption Braak and his team believed that cases of PD could be staged from those 
with no symptoms to those with severe symptoms, and from this order it would be 
possible to deduce the progression of PD from one region within the brain to the next.11 
Braak obtained 41 brains from patients who had a confirmed diagnosis of PD as well as 
69 brains from patients who had none of the characteristic motor symptoms of PD, but 
had the presence of LBs and LNs at various locations within the brain.11 Braak also had a 
control group composed of 58 brains derived from people who had no PD motor 
symptoms or psychological symptoms.11 From the study of these brains Braak derived a 
six-stage classification for PD.11 
 
The first stage is characterized by the degeneration of the olfactory bulb and the anterior 
olfactory nucleus, which is thought to account for the olfactory dysfunction that occurs in 
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many PD patients before the onset of motor symptoms.12 The pathological process 
spreading to the lower brain stem defines Braak’s second stage. The degeneration of the 
lower brain stem is thought to explain the disruption of sleep and other autonomic 
symptoms of PD such as sexual dysfunction. The first two stages in Braak’s system are 
referred to as the pre-clinical stages as the iconic motor symptoms of PD are not seen 
until the third stage. Stage three is when the SNpc begins to develop LNs as well as some 
LBs,11 which results in the motor symptoms that are classically associated with PD.12 
Stage four has the same pathology as stage three, but with additional pathological 
changes occurring within temporal mesocortex.11 Stages three and four are when PD 
shifts from a pre-motor to a motor disorder, and it is at this point when PD is diagnosed.12 
Braak’s stages five and six are classified by the presence of LBs within the limbic system 
and mature neocortex. During these stages patients may develop the symptoms of 
depression, cognitive impairment and visual hallucinations.12 While this staging system is 
helpful, Braak’s system does have a few shortcomings.  
 
This staging system is based solely on the presence on LNs and LBs within the brain as 
opposed to the development of neuronal degradation.12 Additionally, Braak’s system does 
not account for PD patients who present with cognitive symptoms at an early stage, such 
as hallucinations or dementia.12 Braak’s staging also does not account for the 
development of restless leg syndrome (RLS) or constipation as pre-clinical symptoms of 
PD.12 
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The final PD staging scale that will be considered is the Hoehn and Yahr (HY) scale. The 
HY scale has also been incorporated into the Unified Parkinson’s Disease Rating Scale   
(UPDRS), which will be considered in more detail later on. Dr. Hoehn and Dr. Yahr 
proposed the Hoehn Yahr five-stage scale in 1967, as a way to rate the severity of PD in a 
consistent and convenient fashion.13 This scale filled a void because it enabled physicians 
to rank the severity of PD in different patients, and track the progression of the disease, 
while simultaneously assessing the effectiveness of treatment.13 
 
Currently, the HY scale is widely implemented in a modified form that includes two 
additional stages: Stage 1.5 and Stage 2.5. This modified form of the scale will be utilized 
in this study. The modified HY stages are defined as follows: Stage 0, no signs of the 
disease; Stage 1, when PD only effects one side of the body; Stage 1.5, when PD is 
unilateral with axial involvement; Stage 2, when PD occurs bilaterally, but the patient has 
no balance impairment; Stage 2.5, when the patient has mild bilateral disease and when 
the patient is able to recover from the pull test; Stage 3, involves mild to moderate 
bilateral disease with some postural instability, but with physical independence; Stage 4, 
when the disease is severe, but the patient is still able to stand and walk without 
assistance; and, Stage 5, the most severe form of PD, when the patient is unable to get out 
of bed or out of a wheelchair without assistance.8  
 
	8 
Motor Symptoms  
The symptoms of PD are commonly split into motor and non-motor. Motor symptoms are 
frequently the most common first complaint of PD patients and are fundamental to the 
diagnosis of PD.14 There are four cardinal symptoms of PD, which are assembled under 
the acronym TRAP: Tremor, Rigidity, Akinesia (bradykinesia), and Postural instability, 
and these symptoms oftentimes present asymmetrically.15,16,17 
 
Tremor is very useful in the diagnosis of PD, but is not always present in patients.3,14 
Tremors can be observed when the patient is at rest, when the patient is moving or when 
the patient assumes a position.14 In some cases PD patients will report a tremor when 
none is apparent during a physical exam.14 These tremors are called subjective tremors 
and can precede the observable tremors by months or even years.14  The classic tremor is 
the resting tremor, and is most associated with PD.18 Postural tremors are different from 
resting tremors because they usually have a higher rate of oscillation and can be present 
in the absence of resting tremors.18  
 
The severity of a resting tremor is not associated with the severity of dopamine 
deficiency in the substantia nigra.18 The severity of a resting tremor is, however, 
correlated with dopamine depletion in the pallidum.19  Even when a PD patient is treated 
with dopamine replacement therapy, the severity of the tremor might not respond or may 
even worsen depending upon the source of the dopamine depletion.18 Alternatively, 
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treatment with anticholinergic agents has proven to be somewhat effective in treating 
resting tremors in PD patients.18  
 
Currently, the pathophysiology of the resting tremor is an area of research. Some 
researchers have suggested that there are two different mechanisms at work, resulting in 
both resting and postural tremor.18 When the motor cortex is stimulated with a 
transcranial magnetic field, the resting tremor and the postural tremor in PD patients who 
had both types (of tremors) were reset.18 However, when the cerebellum was stimulated 
with a transcranial magnetic field only the postural tremor was reset.18 This difference led 
the researchers to conclude that these types of tremors had different underlying 
pathophysiological mechanisms.18 
 
Rigidity is rarely noticed by patients and is mainly detected by physicians, as patients 
usually report a feeling of general stiffness or pain.2,14 Rigidity can be localized to a 
particular limb, be diffuse throughout the patient’s body or can be localized to the 
patient’s trunk.2 Additionally, rigidity in PD patients can be observed when a patient 
moves a limb opposite to the limb affected by rigidity.2 There are two major types of 
rigidity: ‘lead-pipe’ rigidity, characterized by a constant resistance to passive movement 
when tremor is not present, and ‘cogwheel’ rigidity, characterized by a clicking resistance 
due to the presense of a tremor.2 
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Bradykinesia is the most clinical significant motor symptom of PD as it is not possible to 
diagnose a patient with PD unless bradykinesia is present.14 Bradykinesia is used to 
describe slowness or difficulty in making voluntary movements, and is identified as 
either axial, distal or proximal.14,20 Symptoms of axial bradykinesia include having 
difficulty getting out of a chair, turning over in bed, and difficulty changing the direction 
of movements, while symptoms of distal bradykinesia include having trouble buttoning 
clothes, or tasks such as beating an egg.14  
 
Bradykinesia is also seen in the face of PD patients, where it usually manifests as a 
reduction in spontaneous as well as emotional facial expressions.20 Bradykinesia is 
unique in this regard as tremor and rigidity do not typically affect the facial muscles, 
perhaps due to the difference in physiology between the facial and limb muscles.20 The 
reduction in spontaneous facial movements and emotional facial expression, referred to a 
hypomimia, usually occurs in a bilateral and symmetrical fashion.20 Interestingly, 
hypomimia improves during rapid eye movement (REM) sleep and during rapid eye 
movement sleep behavioral disorder (RBD), which might result from the activation of the 
primary motor cortex and lower motor neurons.20 
 
PD usually progresses faster in patients who are primarily afflicted with bradykinesia and 
rigidity compared to PD patients primarily afflicted with tremor.4,14 There are two major 
subtypes to PD: Akinetic-rigid and Tremor-dominant.4 There is a faster progression of 
disease in PD patients who suffer from the akinetic-rigid subtype, than patients who 
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present with the Tremor-dominant subtype.4 Neuroimaging has shown that tremor-
dominant patients have better preservation of the nigro-striatal pathway, while severe cell 
loss in the substantia nigra pars compacta is associated with the akinetic-rigid subtype.4 
These pieces of evidence are thought to help explain the observed differences in disease 
progression for these two subtypes of PD.4 
 
Postural instability results from the loss of postural reflexes and is usually observed 
during late stage PD.15 PD patients often complain about feeling unstable or having a lack 
of confidence when walking.14 Postural instability is assessed using the pull test where 
the patient is quickly pulled backwards or forwards by the shoulders.15 If the patient takes 
more than two steps backwards or has no postural response as seen by the manifestation 
of an abnormal postural response, then the patient is said to have postural instability.15  
Postural instability is a serious symptom as it can lead to an increase risk of falls.15 
Several PD risk factors are thought to increase postural instability including orthostatic 
hypotension, age, and a decrease in kinaesthetic ability.15 
 
In addition to the four characteristics motor symptoms of PD, many patients also 
experience other motor difficulties, including problems with gait and bulbar symptoms.14  
Common gait problems of PD include slow shuffling strides, accelerating gait, and 
variable stride times.21 There are basically two categories of gait dysfunction: continuous 
and episodic.22 Continuous gait dysfunction is observed as changes in the walking pattern 
of PD patients that are consistent and apparent most of the time.22 Conversely, episodic 
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gait dysfunction occurs intermittently and randomly.22 Two common episodic gait 
disturbances are start hesitation and the freezing of gait.22 Freezing of gait is most 
commonly experienced by patients in the late stage of PD.22  
 
Gait debilitation is a chief complaint of patients, and is a major cause of morbidity and 
mortality in PD because it leads to a loss of independence and is a major cause of falls.22 
The risk of falls are very serious for PD patients as they can cause serious physical 
injuries, such as hip fractures. Falls can also cause a fear of falling that can in turn 
contibute to the institutionalization of these patients.22 One study found that the relative 
risk for falling over a six month period for PD patients compared to healthly controls was 
9.0.22  
 
Bulbar symptoms (otherwise known as speech deficits) include dysarthria (difficulty in 
articulation of speech), hypophonia (abnormally weak voice), dysphagia (difficulty in 
swallowing) and sialorrhea (excessive salivation).14,15 The majority of these symptoms 
present during the later stages of PD. Sialorrhea is the exception as some PD patients may 
initially present with this symptom.14 These symptoms are thought to be related to 
orofacial-laryngeal bradykinesia and rigidity.15 Dysarthria and hypophonia are also 
commonly observed within the elderly population making it unclear if they have a 
pathological relation to PD.23 Dysphagia is often caused by PD patients being unable to 
start the swallowing reflex or by prolonged movements of the larynx or oesophagus.15 PD 
related drooling may also be due to decreased swallowing.15 Furthermore, dysphagia 
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greatly impacts the quality of life of PD patients as it can lead to complications with 
taking medication and can result in aspiration pneumonia, which is a major cause of 
death in PD.24 Sialorrhea can often have many negative sideffects in PD patients such as 
embarrassment, poor oral hygiene and aspiration pneumonia, making it a serious problem 
in PD.25 
 
The Rating of Motor Symptoms  
The current scale used to rate the motor symptoms as well as many other symptoms seen 
is PD is the Unified Parkinson’s Disease Rating Scale (UPDRS). This scale was 
developed in the 1980s and is divided into four parts: Part I, mentation, behavior and 
mood; Part II, activites of daily living (ADLs); Part III, motor exam; and Part IV 
complications.26  Part III of this scale is very widely used in both research and clinical 
practice.26 Overall, however, parts II and III are the most widely used parts of this scale 
in both the clinic and in research.26 Studies have found that the UPDRS scale is most 
useful in the assessment of moderate to severe PD and is not optimally configured to 
address the signs and symptoms of mild PD.26  This scale has been validated, has been 
shown to correlate with the Hoehn Yahr sclae for PD severity, and has both scientific as 
well as clinical credability.26 One of the main drawbacks of this scale is that it does not 
have a comprehensive assessment of the non-motor symptoms of PD.26 This limitation 
has been addressed in a modified form of the UPDRS, which will be discused in the 
rating of non-motor symptoms section. 
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Non-Motor Symptoms 
The non-motor symptoms (NMS) of PD, which include neuropsychiatric symptoms, 
sleep disorders, autonomic symptoms, gastrointestinal symptoms, sensory symptoms, and 
other symptoms such as weight loss, have gone unrecognized for much of the history of 
PD, however, are now known to play an important role in PD.4,27–32 Currently, PD is 
thought of as a multisystem disease associated with the degredation of the dopaminergic, 
serotonergic, noradrenergic and cholinergic systems, all of which play a role in the 
development of NMS in PD. However, more work needs to be done to elucidate the exact 
physiopathology behind NMS in PD because NMS significantly impacts the quality of 
life of PD patients, and are thought to greatly contritube to institutionalization.4,12, 25,30-33 
 
Research has shown that many NMS, such as cognitive impairment, occur during the 
later stages of PD.12,28,34 Other NMS, such as depression, tend to present in the earlier 
stages of PD or may even precede the development of the motor symptoms of PD like 
REM-sleep behvioral disorder (RBD) and olfactory dysfunction.12,28,34 Studies have 
reported that NMS occur with a prevalance of 21% before the initial diagnosis of PD, and 
increase to 88% seven years from the onset of PD.33 Furthermore, it is very common for 
PD patients to exhibit more than one NMS, with many studies reporting patients 
struggling with an average of 9-12 NMS.32,35–37  Possible reasons why NMS frequently 
occur together is that several NMS may share common pathological mechanisms and 
similar secondary triggers.36  For example, depression might result from persistent sleep 
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disturbances or possibly from the constant day to day disability associated with PD.36  
 
Neuropsychiatric Non-Motor Symptoms 
The neuropsychiatric NMS of PD include depression, anxiety, apathy, hallucinations, 
psychosis, dementia and confusion.12,28,34 Depression in PD is thought to result from the 
combined damage of the serotoninergic system, the limbic noradrenergic, and the 
dopaminergic system. 12,38  PD associated depression affects 10-45% of patients and 
tends to precede the classic motor symtopms of PD, making it the most common of the 
neuropsychiatric NMS symptoms.12,28 Interestingly, the occurrence and intesity of 
depression in PD patients is not correlated with the severity of motor symptoms.38   
 
Over the past ten years, apathy, a state of decreased motivation characterized by a 
decrease in goal-directed behaviors, has been established as a distinctive symptom of PD, 
separate from depresssion and fatigue.12,37  Apathy can also be observed as a loss of 
interest which cannot be attributed to a decreased level of cognition, a state of emotional 
distress, or a decreased level of consciousness.39 Apathy is very similar to depression in 
many ways, except it includes the characteristic symtpoms of blunted affect, decreased 
intellectual curiousity, and decreased executive function.39 Twenty-to-thirty-six percent 
of PD patients have been diagnosed with apathy in both the early and late stages of PD.39 
This is an important statistic because apathy is characteristic of the worsening of PD 
because it is predictive of a decrease in functioning of daily activities, in quality of life, in 
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response to therapy, and is indicitive of a poor outcome.39 Hallucinations, like apathy, are 
also indicative of a decrease in daily functioning. 
 
As many as 40% of patients, during the follow-up stages of PD experience 
hallucinations.28 Visual hallucinations (VH) are the most common hallucinations 
experienced by PD.12,40 Rarely, auditory hallucinations (AH) have been reported 
independently of or along with visual hallucinations.12,40 Hallucinations were traditionally 
thought of as resulting from treatment with levodopa, but are now recognized as an 
intrinsic symptom to PD.41  The presence of VH in PD patients has been associated with 
the presense of lewy bodies as well as lewy neurites in the limbic system, frontal cortex, 
temporal lobe, and parietal lobe.41 Hallucinations in PD have also been greatly associated 
with sleep dysfunction, which will be futher discussed in the sleep dysfunction part of 
this paper.41,42  VH are also predictive of cognitive decline and the future development of 
dementia, which will be discussed further.41 
 
Dementia is another characteristic symptom of PD, occurring in up to 40% of patients (6 
times the rate of observed in apparently healthly individuals).12,28 Dementia in PD is 
characterized by a loss of visio-spatial abilities and memory, and a decrease in attention 
span and verbal fluency.28,34 Dementia is progressive in PD and is thought to result from 
the degeneration of dopamenergic nigral cells as well as cholinergic cell loss in the 
nucleus basalis of Meynert.12.  However, studies have shown that the most significant 
predictors of dementia were age, decreased semantic fluency, and difficulty in pentagon 
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copying.34 Additionally, PD patients who initially presented with mild cognitive 
impairment (MCI) were also shown to be at greater risk of developing dementia than 
patients who did not present with MCI.34  
 
Sleep Disturbance 
Sleep disorders, another common NMS of PD, are estimated to affect between 40-90% of 
patients and tend to increase with the severity of PD.43 This wide distribution can be 
attributed to differences in study populations and methodologies used throughout 
different studies.43 While the impact of sleep disorders are quite expansive, sleep 
disorders are a significant problem in PD as they can occur during any and all stages of 
PD and tend to increase with the severity of PD; there are limited treatments available; 
and, they have a significant impact on the health related quality of life (HRQoL) and 
social functioning of PD patients.43,44 Interestingly, patients often do not report sleep 
disturbance when asked.43 REM sleep behavioral disorder (RBD) is one of the most 
heavily researched sleep disorders that is commonly observed in PD, and will be more 
thoroughly considered here.   
RBD is characterized by patients acting out their dreams during sleep resulting from the 
pathologic loss of muscle atonia which acompanies REM sleep.44,45 Movements 
associated with RBD, including punching, kicking, leaping out of bed, talking, shouting, 
crying, laughing, and singing, appear to be purposeful and tend to be violent in nature, 
potentially placing both the patient and their sleeping partner at risk of injury.42,43,45,47-51  
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REM sleep atonia provides a protective function as it allows humans to have physically 
engaging dreams without actually resulting in any of the physical movements during 
sleep, preventing them from harm.48 The dreams that occur often have a negative context 
to them, and often involve violence where the patient is rarely the one initiating the 
violence within the dream.45,48,49 In fact, a study conducted by Olson et al showed that 
98% of patients with RBD report defending against an attacker during their violent 
dreams.49 
 
RBD has received a lot of attention from the research community as this symptom is 
highly associated with PD and has even been reported to occur years before the clinical 
manifestation of PD symptoms. RBD has been estimated to have a 30-60% prevalance in 
PD patients, which is signficantly higher than estimates (of RBD) in the general 
population (0.5%).42,47,50  
 
There is some evidence to suggest that PD patients who initally present with RBD are at a 
greater risk for developing dementia as well as VH compared to PD patients who do not 
initally present with RBD.41,45,47,51  In an 8 year follow-up study conducted by Onofrj et 
al, RBD was found to be an independent predictor of VH in PD.51 Additonally, studies 
have found PD patients with RBD to have three times the risk of developing VH as 
compared to PD patients without RBD, and up to 50% of PD patients with RBD have 
hallucinations in general.45 Gagnon et al also demonstrated that 73% of PD patients with 
RBD exhibited mild congitive impairment, whereas only 11% of PD patients without 
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RBD showed only mild conginitive impairment.52 Similarly, Postuma et al. found that, 
over a 4 year follow-up period, 48% of PD patients with RBD developed dementia 
compared to 0% of PD patients without RBD.53 Interestingly, all of the patients in this 
study who developed dementia exhibited mild congitive impairment during the beginning 
stages of the study, suggesting that mild cognitive impairment, RBD and dementia might 
be interrelated in PD.53 Finally, there also appears to be a male predomince of RBD in PD 
patients.43  
 
Insomina is a nonspecific symptom commonly reported amongst PD patients, as studies 
have shown that 60-76% of PD patients have insomnia.50,54 Insomia is classified by a 
variety of symptoms including sleep initiation problems, sleep fragmentation or early 
awakenings, poor sleep quality, as well as non-restorative sleep, and has been shown to 
have a great impact on the HQRoL of PD patients.50,55  Insomnia is one of the most 
subjective complaints in PD as each individual experiences the severity of insomnia 
differently, there are many different causes of insomnia, there is a large variability in how 
long the insomia lasts, and it is difficult to stage the intensity of insomnia through 
questionnaries.55 All of these different factors are believed to play a role in the large 
difference in which PD patients report insomia.55 Further, several other common PD 
symptoms have also been linked to insomnia, such as depression and motor symptoms.  
 
Depression, motor symptoms, and nocturia are also thought to play a role in the 
development of insomnia. It is not clear if insomnia causes depression or if depression is 
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a cause of insomnia, but the two have been correlated in many different studies.56  
Furthermore, the medication perscribed to PD patients to mitigate the motor symptoms of 
PD, such as levodopa, have the potential to disrupt sleep as well.55 Insomnia has been 
reported to occur during the early stages of PD.56 The presence of insomnia during the 
early stages of PD is consistent with Braak’s hypothesis of PD progression as Braak 
found that the brain regions reponsible for sleep/wake regulation develop lesions 
relatively early on in the development of PD.11 Lastly, the frequency of insomia in PD 
patients has been found to correlate with increased disease severity in PD patients.50 
Another common sleep disorder thought to contrbute to insomia is restless leg syndrome.  
 
Restless leg syndrome (RLS) was first described in 1945 by Dr. Karl-Axel Ekbom.57 RLS 
and PD are commonly associated, but the pathophysiology behind RLS in PD is curently 
a topic of debate as it remains unknown if RLS and PD share common pathophysiologic 
mechanisms.58 RLS does, however, respond to dopaminergic drugs indicating that there 
could be some similar pathological process to PD.59 RLS, unlike RBD, is not recognized 
as a pre-clinical symptom of PD, and RLS is not associated with the risk of devleoping 
PD.43,57 No clear risk factors for the occurance of RLS in PD patients have been 
identified, however, RLS appears to be less severe in PD patients than in the general 
population.58 RLS symptoms occur relativly late in PD patients as RLS symptoms have 
mainly been shown to occur after the onset of the PD motor symptoms.43,58 Most of the 
PD patients who go on to develop RLS do not have a family history of RLS, suggesting 
that there is no prominent genetic factor playing a role.43,58,60 Females have also been 
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found to have a more frequent occurrence of RLS within the general population, but this 
gender distribution of RLS has not been seen in PD patients.58,60  
 
Many of the symptoms associated with RLS occur in PD patients who do not have RLS.58 
Akathisia, when a patient has an inner restlessness with an urge to move, is a major 
overlapping symptom between PD and RLS as akathisia is usually reported in late stages 
of PD in patients who both receive and do not receive dopamine replacement therapy.58,61 
Akathisia is still a current topic of research as it is not clear if akathisia and RLS are two 
separate conditions or if they are part of the same spectrum of motor restlessness in PD.58 
In addition, RLS symptoms are closely mimicked by sensory and fluctuating symptoms 
in relation to dopaimergic treatment within PD patients, making the distinction even more 
difficult.58 RLS has been known to occur secondarily to other medical conditions like 
iron deficency anemia, end stage renal disease, diabetes mellitus, and rheumatoid 
arthritis.62,63 Furthermore, more studies need to be done to address the proper way to teat 
PD patients who have RLS and RLS like symptoms, as no studies have been done on this 
topic and the current methodology used to treat these patients comes from treatments that 
are used in idopathic RLS.57,58 
 
Currently, sleep disordered breathing has not been extensivly studied in PD. Obstructive 
sleep apnea (OSA) is the most common form of sleep disordered breathing. Past studies 
have indicated that OSA is more prevalent in PD patients as compared to healthy 
controls, but more recent studies have shown that the prevalence of OSA is not 
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significantly different between PD patients and healthy controls.43,45 Additionally, no 
relationship has been established between OSA, disease severity, the duration of disease, 
daytime sleepiness, nocturia, depression, and congnitive impairment in PD patients.43,45 
This lack of association seems to indicate that PD and OSA may not be related to one 
another. 
 
Excessive daytime sleepiness (EDS) is commonly observed as a persistent sleepiness that 
can occur from both inadequate and adequate quality and duration of sleep.44 EDS occurs 
in up to 50% of PD patients.43,45,50 The etiology behind EDS is thought to be multifactoral 
as it is thought that EDS results from the degeneration of the cholinergic, serotoninergic, 
noradrenergic, and orexin systems.43–45 This makes sense because EDS is common to 
neurodegenerative diseases in general like Alzheimers Disease and PD.44. Sleep disorders 
like RLS and insomnia are also thought to play a role in the development of EDS within 
PD patients, although an association has not been found between nocturnal sleep 
disturbances and EDS.45 
 
Additional Non-Motor Symptoms 
There are many other NMS that occur in PD and they will be briefly mentioned here. 
These other NMS include: orthostatic hypotension, sexual dysfunction, bladder 
distrubances, sweating, and xerostomia (dry eyes), nausea, vomiting, constipation, 
defecatory dysfunction, pain, paresthesia and olfactory dysfunction. 12,64–66  
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This section will specificlly focus on  orthostatic hypotension, sexual dysfunction, 
constipation, pain, and olfactory dysfunction. 
 
Orhtostatic hypotension (OH) results, in patients seeing black spots within the visual 
field, dizziness, faintess, and the loss of conciousness.67 OH is a major problem in PD 
because it has an impact on the mortality67 of the PD population and can cause physical 
injuries by inducing falls.68 Sexual dysfunction is not highly prevelent in PD8 and both a 
decreased and abnormally high sex dirve have been reported by patients.12,28 Sexual 
dysfunction has also been reported more in males than females, although both sexs have 
reported changes in sexual activey after the onset of PD.69 Constipation is generally 
defined as less than three bowel movements per week.64 Additionally, conspitation is now 
recognized as a symptom that can occur before the onset of the cardinal motor symtpoms 
in PD,8,70 with some studies reporting that constipation can occur 18 years before the 
onset of the diagnostic motor symtpoms.8 Pain is very prevelent in PD as it effects about 
54% of patients, but is often undertreated. 71,72 Pain has also been found to be the leading 
factor on the physical HRQoL of early stage PD patients, making it an important issue 
from the patients prospective.71,72 Olfactory dysfunction is hugely prevelent in PD as it 
occurs in about 90% of PD cases.28,73 Olfactroy dysfunction is also particularly 
interesting as it is a pre-clinical symptom of PD.12,73–75 Furthermore, people who have 
olfactrory dysfuncation have been shown to be at an increased risk of developing PD in 
the future.73,75  
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Rating of Non-Motor Symptoms  
Now that some of the various NMS of PD have been discussed, this paper will now 
briefly go through some of the major tools that are used to research and detect the NMS 
of PD both in the research and clinical setting. NMS have been becoming more 
researched in the PD literature over time, which eventually led to the creation of the NMS 
questionnaire in 2006 by a panel of experts.29 The NMSQuest is a screening 
questionnaire that is not intended for the assessment of the severity of NMS in PD.29 This 
questionnaire is composed of 30 items that are to be completed by the patient with the 
patient indicating yes or no box next to the described symptom.29 The questionnaire 
groups the NMS of PD into 10 different catagories: gartrointestinal tract, urinary tract, 
sexual function, cardiovascular, apathy/attention/memory, hallucinations/delusions, 
depression/anxiety/anhedonia, sleep/fatigue, pain, and miscelaneous (ex wieght loss).29  
 
A limitation of the NMSQuest is the fact that it cannot rate the severity of NMS in PD 
patients, resulting in the development of the Non-Motor Symptoms Scale (NMSS) in 
2007. One of the major differences between the NMSQuest and the NMSS, is that a 
physician is the one who records the NMS experienced by the patient instead of the 
pateint themselves.76 The NMSS is a 30 item survey which records both the frequency, 
from 1-4, and the severity, from 0-3, for NMS.76 The frequency and severity are then 
multiplied together in order to give a numerical score for each of the 30 items.76 
Accordingly, the NMSS is able to capture symptoms that are severe and infrequent as 
well as those that are frequent and not severe.76  
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The NMSS was initally studied in 242 PD patients in the UK, Italy, Germany, Japan, and 
the US by Chaudhuri and his team in 2007.76  In this study the NMSS score of PD 
patients was found to increase as the severity of the disease increased as meaured by 
Hoehn and Yahr stages (HY).76 The NMSS is intended to be used to obtain a holistic 
assessment of the severity and frequency of NMS in PD, not as a diagnostic pannel for 
NMS is PD.76  
 
In addidition to both the NMSQuest and the NMSS, there are many other scales that can 
be used to look for the presence as well as the severity of NMS in PD. The most inclusive 
NMS scale after the NMSQuest and the NMSS is the modified version of the unified 
Parkinson’s disease rating scale (UPDRS), developed by the Movement Disorder Society 
in 2008. The modified scale is called the movement disorder society-unified Parkinson’s 
disease rating scale (MDS-UPDRS). This scale is very similar to the UPDRS except that 
it has an additional section that covers NMS in PD.  
 
The MDS-UPDRS covers several NMS such as sleep problems that occur both in the day 
and during the night, pain, urinary problems, constipation, and salivation.77  Furthermore, 
the MDS-UPDRS differs from that UPDRS in that symptoms are reported as 
slight/mild/moderate/severe from mild/moderate/severe/marked, making it easier to 
detect early symptoms of PD.26 Therefore the MDS-UPDRS will most likely be utilized 
more in the future as clinical trials begin focusing on the early symptoms of PD.26 
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Finally, the MDS-UPDRS has been shown to perform very well in comparison to the 
UPDRS and has been validated.26  
 
Sex 
The role that sex plays in the development and manifestation of different PD symptoms 
has not been well studied in the past, but is an active subject of current research. There 
has been an increase in interest in the impact biological sex has on the development of 
PD because PD appears to affect men and women differently.  
 
There is a difference in the prevalence and incidence of PD amongst men and women, as 
PD is seen more commonly in men across all ages and ethnic groups.78,79 The incident 
rates of PD in men compared to women range from 1.37 to 3.70, respectively.78 
Additionally, men are two times as likely to be diagnosed with PD than women.79 Studies 
have also suggested that women have a greater average age of PD onset than men, 
however different studies have reported different ages of onset in each gender.78,79 The 
difference in the observed ages of onset between studies is most likely due to differences 
in the sampled populations studied.79  
 
There also appears to be some differences in the presentation of motor and 
neuropsychiatric symptoms associated with PD in both sexes. Women tend to have a 
delayed onset of certain motor symptoms and are more likely to present with the tremor-
dominant subtype of PD.78,79 This observation is interesting as the tremor-dominant 
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phenotype of PD has been associated with a slower progression of PD as measured by the 
UPDRS.79 Some experts suggest that the observed delay of onset of motor symptoms in 
females could be due to higher levels of dopaminergic activity in women, however, this 
notion is not supported in the research.79 Women are more likely than men to report 
greater disability and a lower quality of life, however this finding is not unique to PD as 
women, compared to their male peers, are more likely to report a functional 
disadvantage.79 One study found that women have greater difficulty with postural 
instability as compared to men.79.This is of clinical importance because women are more 
prone to falls than men and have a lower bone mineral density than men, which also 
increases their risk of sustaining a fracture.79 
 
Women are at a higher risk of developing cognitive decline, dementia, depression, 
constipation and dyskinesia, a common side-effect of levodopa treatment, as compared to 
men.78–80 On average women take higher doses of levodopa per kilogram of body weight, 
which is thought to play a role in the observed difference of dyskinesia reporting between 
the sexes.80 Men are more likely to have EDS, dribbling and sexual symptoms.78 There 
have also been observed differences in sleep disorders between the two sexes with a 
higher prevalence of RBD in men than women.78–80 Researchers have called into question 
the role estrogen might have in PD patients. Many studies focusing on estradiol have 
shown that estradiol has a neuroprotective effect, however, most of the evidence comes 
from animal models.78 Finally, sex genes are also being investigated as the SRY gene 
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(responsible for determining the male sex on the Y-chromosome) is expressed in a subset 
of dopaminergic neurons in the SNpc in males.78  
	
Race 
The impact of race on the outcome of patients with PD has only recently begun to be 
studied. Currently, epidemiology studies have not focused on the distribution of PD in 
non-whites within the US.81 Past studies have shown conflicting evidence regarding the 
distribution of PD within different races with studies showing that different races have 
the highest prevalence of PD.81,82 They also found a much higher prevalence of PD in 
Whites as compared to Black and Asians, which seems to suggest that there is a genetic 
component driving this observed difference.81  
 
Even though previous studies appear to shows that Blacks suffer more severely from PD, 
it is unclear if the increased morbidity is due to biological reasons or due to a difference 
in timing of PD diagnosis. Studies have found that Blacks were more likely to be 
diagnosed at a later stage of PD than their White peers.83,84 Additionally, it has been 
observed that Blacks report less motor disability than Whites when both had the same 
level of motor impairment.83 The under-reporting of motor disability in Blacks accounts 
for a significant difference of the stage at which Blacks where diagnosed as compared to 
Whites.83 These studies suggest that the observed increase in mortality of PD patients 
who are Blacks is caused by the later stage at which Blacks receive their PD diagnosis. 
Overall, it is important to consider both biological, socioeconomic, and access to health 
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care resources when trying to deduce the cause behind the increased mortality associated 
with Blacks who have PD.82 
 
Treatment Methodologies  
There are many different types of treatments used for PD. Currently, all the treatments 
that are used to treat PD simply reduce the symptoms associated with the disease, having 
no effect on the rate of neurodegeneration characteristic of neuropathology in PD. A 
majority of the current research on PD treatment is focusing on new therapies that will 
have a neuroprotective effect and thus will slow the progression of PD. The 
pharmacologic therapies that will be considered in this section are levodopa (L-dopa), 
monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) 
inhibitors, and dopamine agonists (DA).  
 
The use of levodopa in PD began in the early 1960s and was approved by the FDA in 
1967. Levodopa (L-dopa) is still considered the “gold standard” treatment in PD today, 
and the development of L-dopa is viewed as one of the most important advances in the 
treatment of neurodegenerative disorders. L-dopa is a precursor of dopamine and is 
readily converted to dopamine in the peripheral tissues as well as within the brain.8 Once 
L-dopa reaches the brain it is taken up by striatal neurons that subsequently convert L-
dopa into dopamine, resulting in an increased amount of dopamine within the brain, 
reducing the motor symptoms of PD patients.8 L-dopa treatment is limited in that it has a 
short half-life of approximately 90 minuets that is mainly due to the actions of aromatic	
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amino	acid	decarboxylase (AAAD) and COMT.8 Many physicians will often prescribe 
an AAAD inhibitor, carbidopa or benserazide, as well as a COMT inhibitor with L-dopa 
resulting in an increased bioavailability of L-dopa within the blood stream.8 COMT 
inhibitors are also thought to help to smooth out the levels of L-dopa within the plasma 
over time, allowing for a more continuous delivery of L-dopa, which is thought to help 
reduce motor fluctuations as well as dyskinesia.8  
 
MAO-B inhibitors are also frequently used to treat PD. MAO-B is an enzyme that plays 
an integral role in the metabolism of dopamine within the CNS. MAO-B inhibitors are 
thought to be beneficial to PD patients by preventing the degradation of dopamine by 
MAO-B in the CNS, inhibiting dopamine reuptake, and indirectly promoting the 
increased release of dopamine.8 Interestingly, MAO-B inhibitors have been shown to 
have neuroprotective effects in both cellular and animal models through multiple 
mechanisms such as down regulating proapoptotic proteins, up regulating antiapoptotic 
proteins, and increasing the amount of antioxidant enzymes.8 
 
Dopamine agonists (DA) are synthesized molecules that bind to dopamine receptors.  
DAs are thought to have several advantages over levodopa in terms of their 
pharmacokinetic and pharmacodynamic properties. DAs do not have to be converted or 
stored in nigrostriatal neurons as they act directly on the dopamine receptors.8 
Additionally, DAs are not metabolized by the liver as readily as L-dopa is, allowing for 
more of the DA to be available in the systemic circulation after the first pass.8 
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Furthermore, DAs have a longer half-life than L-dopa allowing for higher levels of active 
chemical within the systemic circulation over time8. DAs are limited in that they are not 
tolerated as well as L-dopa is by patients as they are associated with a higher rate of 
occurrence of orthostatic hypotension, nausea and vomiting.8 Sleep disturbances are also 
commonly reported with both DA and L-dopa therapy, with the sudden onset of sleep 
being the most troubling.8  
 
Conclusion 
The primary objective of this study is to determine how race, sex and sleep disturbance 
impact the severity of PD as recorded by the modified HY scale in the ON and OFF 
medication states, while controlling for the confounders of age and time in years from 
onset of PD symptoms to database entry. The current literature on how PD impacts 
different races is inconclusive as some studies suggest that there is a biological difference 
causing the observed differences in PD severity between the races while others suggest 
that socioeconomic factors explain these differences. Sex has also just recently been 
studied in PD and it is still unclear how sex impacts PD symptoms and severity. 
Additionally, sleep disturbance has been shown to greatly impact PD patients and 
therefore it will be interesting to see how disease severity is impacted in PD patients with 
sleep disturbances at Boston University Medical Centre (BUMC).  
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METHODS  
 
Patient Recruitment and Data Collection  
This cross-sectional study sought to assess how race, sex, and sleep disturbance impacted 
the severity of PD in both the ON and OFF medication states as measured by the HY 
scale. All of the data used for the analysis in this thesis was obtained from the Movement 
Disorders Database kept by the Boston University Medical Center’s (BUMC) Movement 
Disorder Clinic (MDC). Patients were included in this study if a movement disorder 
specialist from the MDC diagnosed them with a movement disorder, such as PD or PSP. 
The movement disorder specialists collected the relevant information for the database by 
completing a survey and referring to medical records to verify the accuracy of the 
information obtained. The data collected on the HY scores both in the ON and OFF 
medication states were obtained from the medical records. This study included data from 
patients seen at the MDC from 2007-2012. A total of 673 subjects were included in the 
Movement Disorders Database, of whom 452 patients were diagnosed with PD.  Only the 
PD patients were included for the analysis for this study. 
 
The data from the Movement Disorders Database were saved on a password protected 
flash drive with the database itself being password protected as well. All patient 
information was de-identified and the BUMC IRB approved this project. 
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The primary objective of this study was to determine how sleep disturbance, sex, and race 
impacted the severity of PD in both the ON and OFF medication states as measured by 
the HY scale. The confounding factors of age, education, and time in years from the onset 
of PD symptoms to database entry, where all controlled for to better assess the impact the 
primary predictive variables had on HY scores both in the ON and OFF states. The 
secondary objectives of this paper sought to analyze the correlations between 
hallucinations, dementia and autonomic symptoms and HY ON and HY OFF scores. This 
secondary analysis was done to get a better idea of how other NMS impacted HY scores. 
Additionally, this secondary analysis was completed because the large amount of missing 
sleep disturbance data made it difficult to determine what correlation sleep disturbance 
had with HY ON and OFF scores. Therefore, it seemed appropriate to look at what 
relationships dementia and hallucinations had with HY ON and OFF scores as both of 
these symptoms are thought to be impacted by sleep disturbance. 
 
Information Collected in the Survey 
The survey collected information on patient demographics, movement disorder disease 
diagnosis, family history, current or past medications used, and surgical treatment 
undergone by the patient. The types of medications included in the survey were not 
limited to common PD medications like levodopa, but also included any sort of general 
medications that patients were taking such as anti-inflammatory agents. Additionally, the 
patients full name, date of birth, current address, primary language, and insurance type 
were also collected. In the de-identified database used for the analysis of this study, the 
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patient’s full name, address, day and month of birth, were all omitted from the data set to 
ensure the confidentiality of patient information. Data collected on the patient’s racial 
background, and highest level of education achieved were recorded with regards to 
predetermined categories. Furthermore, the occupational background of the patient was 
also collected. The date of onset of the movement disorder, the date of diagnosis of the 
movement disorder, and any disease diagnosis in the patient’s grandparents, parents, 
siblings or children were also collected. The types of diagnoses that were collected on the 
patient’s next of kin pertained to neurological disorders, such as dementia, depression and 
dystonias. This survey also collected information on common complications associated 
with medication such as dyskinesia and motor fluctuations. Additionally, this survey also 
included categories pertaining to the common NMS associated with PD such as sleep 
disturbance, depression, dementia, hallucinations, psychosis, compulsive behaviors, 
freezing of gait, orthostatic hypotension, and other autonomic symptoms. 
 
Statistical Analyses 
All statistical analysis was conducted using R version 3.2.3. All missing data was handled 
such that it was eliminated from statistical analysis. Race was modified by combining 
many subcategories in order to obtain a large enough sample to include in statistical 
modeling and testing. The survey consisted of the following African racial categories:  
African-Black (Sub-Sahara), African North (originating from Sahara or Northern 
Regions: Algeria, Egypt, Morocco, Tunisia, Ect.), and African- Black (those of African 
decent originating from Canada, Caribbean, Brazil, US,). These categories were all 
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combined into the African category. All other racial categories, including: Asian-East 
(originating from China or Japan or Korea), Asian-West (originating from Bangladesh, 
India, Iran, Iraq or Pakistan), American Indian/Alaskan native, Native Hawaiian/Pacific 
Islander, Mixed Race, and other, were combined into the ‘Other’ racial category. The 
Spanish and Caucasian racial categories were maintained. Otherwise no other data was 
combined and the data was left in the original form.  
 
The objective of this study was to examine the differences between HY scores ON and 
OFF medication as they related to sleep disturbance, race, and gender. Secondary 
analyses were conducted to assess the effects of dementia, depression, hallucinations and 
autonomic dysfunction on HY scores ON and OFF medications. Lastly, the potential 
confounding effects of age, the time from disease onset to entry into the Movement 
Disorders Database, and education were assessed. Several different statistical tests were 
used to analyze the association between the primary predictors, secondary predictors and 
confounders.  
 
The differences between the means in HY scores ON and HY OFF medication between 
patients who reported sleep disturbances, who did not report sleep disturbances, and 
patients who were not asked about sleep disturbances were compared utilizing a student 
t-test. A t-test was used instead of a one-way ANOVA because the main comparison of 
interest was between patients who reported sleep disturbances versus patients who did not 
report sleep disturbances. A student t-test was also used to determine if the differences in 
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mean HY scores ON and HY OFF medication was statistically different between sexes. 
The comparisons of means in HY scores ON and OFF medication for race were analyzed 
using a one-way ANOVA test. If statistical significance was found between the various 
means in HY scores ON and OFF medication for the different racial categories, a Tukey-
Kramer test was run to determine the statistical difference between individual racial 
subgroups.  
 
The confounding variables were analyzed in a similar fashion as the primary outcome 
variables. A one-way ANOVA test was also used to determine if a statistically significant 
difference was present in the mean HY scores ON and HY OFF medication for the 
various educational subgroups. A Tukey-Kramer test was used in conjunction with the 
one-way ANOVA if a statistical difference was found. The confounders of age and time 
difference in years from the onset of disease symptoms to entry into the database were 
analyzed using univariate linear regression. A linear regression model was chosen 
because the modified HY score used in the database consisted of nine separate categories, 
allowing the outcome variable of HY scores to be treated as continuous. Additionally, the 
HY scores also have a rough normal distribution and thus a linear regression model 
seemed most appropriate for the data. 
 
After the initial analysis, several univariate and multivariate linear regression models 
were built with the HY scores ON and OFF medication serving as the outcome variable. 
A total of six univariate linear regression models, for each of the predictor and 
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confounding variables, were run for both HY scores ON and HY OFF medication. A total 
of four multivariate linear regression models were built, but only the two excluding sleep 
disturbance as a predictor are included. The two models including sleep disturbance 
models provided some useful information, but were limited in that most of the data on 
sleep disturbance was missing, causing these models to have a very small sample size. 
Therefore sleep disturbance was eliminated in the additional models reported in this 
thesis.  
 
Finally the association between HY scores ON and OFF medication and the NMS of 
depression, dementia, hallucinations and autonomic dysfunction were assessed. These 
variables were chosen because past literature has shown that they have a great impact on 
the HRQoL of PD patients, however, research on how these variables affect HY scores 
both ON and OFF medication states is limited. A multivariate linear regression model 
was run on these variables and HY scores ON and OFF medication to determine how 
these NMS impact HY ON and OFF scores. All linear regression models were reported 
with the calculated regression estimates, 95% confidence intervals around the calculated 
estimates, p-values obtained for each reported estimate, and the r2 value. The r2 value is 
used to indicate how well the regression line fits to the data. Taking the explained 
variance and dividing it by the total observed variance calculates the r2 value. The 
calculated number ranges between zero and one. Generally, a larger r2 value is indicative 
of a superior model fit. However, it is very common to have small r2 values when 
working with human data, as there is a lot of variance between people in general. Finally, 
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a small r2 value does not mean that the results of a linear regression are not meaningful as 
the estimates still provide valuable information on how the outcome variable changes 
with a one-unit change in the predictor variable. 	 	
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RESULTS 
Age, Sex, Sleep Disturbance & Education 
Table 1: Age, Sex, Sleep Disturbance, and Education Break Down Predictors	 Number		 Percentage	
Age:		 	 	0-9	 1	 0.2	20-29	 1	 0.2	30-39	 2	 0.4	40-49	 14	 3.1	50-59	 82	 18.1	60-69	 131	 29	70-79	 153	 34	80-89	 56	 12.4	90-99	 5	 1.1	
Sex:		 	 	Male		 261	 57.7	Female	 184	 40.7	
Sleep	Disturbance:		 	 	Yes	 54	 11.9	No	 90	 19.9	
Race:		 	 	Caucasian		 375	 83	African		 28	 6.2	Spanish		 17	 3.8	Other	 19	 4.2	
Education:		 	 	Less	Than	High	School	 17	 3.8	Some	High	School/	No	Degree	 14	 3.1	High	School	Degree/GED	 83	 18.4	Associates	Degree		 10	 2.2	Some	College/	No	Degree	 36	 8	Bachelor’s	Degree	 110	 24.3	Graduate	or	Professional	Degree	 109	 24.1	
Time	from	Onset	to	Database	Entry	 	 	0-4	Years		 106	 23.5	5-9	Years		 108	 23.9	10-14	Years	 20	 15.5	15-19	Years		 45	 10.0	20-24	Years		 19	 4.2	
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25-29	Years		 9	 2.0	30-34	Years		 4	 0.9	35-39	Years		 2	 0.4	
 
Table 2: Original Racial Categories 
Racial	Groups		 Number		 Percent		African	-	Black	(Sub-Sahara)	 1	 0.2	African	-	North	(Sahara	or	Northern	Regions:	Algeria/	Egypt/	Morocco/	Tunisia/	Etc.)	 4	 0.9	Black-(African	descent/	Originating	in:	Canada/	Caribbean/	Brazil/	US/	etc.)	 23	 5.1	American	Indian/Alaska	Native	 6	 1.3	Asian	-	East	(China/	Japan/	Korea/	etc.)	 9	 2.0	Asian	-	West	(Bangladesh/	India/	Iran/	Iraq/	Pakistan/	etc.)	 2	 0.4	Caucasian	 375	 83	Mixed	Race	 1	 0.2	Native	Hawaiian	or	Other	Pacific	Islander	 1	 0.2	Spanish	(Cuban/Iberian	Peninsula/	Mexican/South	or	Central	American/	or	Other	Spanish	Origin)	 17	 3.8	Missing	Information:		 13	 2.9	
 
Sixty-three percent of the study population ranged in age between 60 -79 years, and the 
study population had a mean age of 68.4 years  (+/- 10.5 year SD) (Table 1). The age 
distribution of the population appears to be approximately normally distributed. The 
study population was mostly composed of males, 57.7%, and was primarily Caucasian, 
83%. The second largest racial category, 6.2% of the overall population, was African 
(Tables 1 & 2). The educational background of the study population was fairly evenly 
distributed with 48.4% of the study population having earned a college degree or higher. 
Lastly, the time in years from onset of PD symptoms to database inclusion ranged from 
0-40 years, with 47.4% of subjects added (to the database) between 0-9 years of symptom 
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onset. Overall, the average amount of time from the onset of PD symptoms to inclusion 
in the movement disorders database was 9.4 years (+/- 7 yrs. SD). 
Missing Data 
Table 3: Missing Data for Predictors, Confounders, and Outcome Variables 
Predictors		 Number		 Percentage	Age	 7	 1.5	Sex	 7	 1.5	Sleep	Disturbance		 308	 68.1	Race		 13	 2.9	Education		 73	 16.2	Time	from	Onset	to	Database	Entry	 89	 19.7	
Outcome		 Number		 Percentage	Hoehn	Yahr	ON	 60	 13.2	Hoehn	Yahr	OFF	 60	 13.2	
 
Table 4: Sleep Disturbance Data by Racial Categories 
Race		 Yes		 No	 Missing	Sleep	
Data	African		 4	 6	 18	(64%)	Caucasian		 40	 73	 262	(73%)	Spanish		 2	 6	 9	(53%)	Other		 4	 3	 12	(63%)	Race	Missing	 4	 2	 7	(54%)	
 
Table 5: Sleep Disturbance by Sex 
Sleep	
Disturbance		
Male		 Female		 Missing	Gender	Yes		 37	 17	 2	No	 57	 33	 0	Missing	Sleep	Data	 167	(64%)	 134	(72.3%)	 7	
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Table 6: Hoehn Yahr OFF and ON Medication Scores Break Down:  
HY	Stage:		 HY	OFF	 HY	OFF	Percent	 HY	ON	 HY	ON	Percent	0	 23	 5.1	 285	 60.3	1	 25	 5.5	 8	 2.0	1.5	 14	 3.1	 2	 0.4	2	 144	 32.0	 21	 4.6	2.5	 49	 11.0	 23	 5.1	3	 64	 14.2	 22	 4.9	3.5	 2	 0.4	 1	 0.2	4	 45	 10.0	 13	 2.9	4.5	 2	 0.4	 0	 0	5	 24	 5.3	 17	 3.8	
Total	 392	 -	 392	 -	
Mean		 2.5	 -	 0.8	 -	
SD	 1.2	 -	 1.5	 -	
 
 
Missing data for every data category is represented in Table 3. The most significant 
amount of missing data came from the sleep disturbance variable. The 308 patients 
missing sleep disturbance data, 68.1% of the study population, resulted from these 
patients not being asked about sleep disturbance by the movement disorder specialist. 
The missing sleep disturbance data seems to be distributed evenly amongst the various 
racial categories in terms of percentages (Table 4). Additionally, sleep disturbance data 
had a higher percentage of missing data amongst females, 72.3% versus 64%, for females 
and males, respectively (Table 5).  Age, sex and race had little missing data. A little more 
than 10% of data was missing from both the HY ON and OFF scores (Table 3) and the 
distribution of both the HY ON and HY OFF scores are given by Table 6. 
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Difference in Mean HY ON and OFF Score 
Table 7: Difference in Means of HY ON and HY OFF Score 
Predictors		 HY	ON	Score		
Mean	(SD)	 HY	OFF	Score	Mean	(SD)		
Sex:		 	 	Male		 0.81	(1.4)	 2.40	(1.2)	Female	 0.81	(1.5)	 2.60		(1.1)	P-value	t-test		 0.95	 0.05*	
Race:		 	 	Caucasian		 0.80	(1.5)	 2.5	(1.2)	African		 1.04	(1.7)	 2.4	(1.4)	Spanish		 0.56	(1.4)	 2.2	(0.8)	Other		 0.46	(0.9)	 2.2	(0.9)	P-Value	ANOVA		 0.60	 0.70	
Sleep	Disturbance:	 	 	Yes	 2.7	(1.2)	 1.1	(1.8)	No	 2.6	(1.3)	 0.8	(1.6)	Missing	Data		 0.7	(1.3)	 2.4	(1.1)	P-value	t-test	=>	Yes	vs.	No	 0.71	 0.30	
Education:		 	 	Less	Than	High	School	 0.7	(1.7)	 2.8	(1.4)	Some	High	School/	No	Degree	 1.3	(2.1)	 3.0	(1.4)	High	School	Degree/GED	 0.8	(1.5)	 2.3	(1.0)	Associates	Degree		 0.3	(1.0)	 2.7	(1.1)	Some	College/	No	Degree	 1.0	(1.4)	 2.5	(1.2)	Bachelor’s	Degree	 0.8	(1.4)	 2.4	(1.1)	Graduate	or	Professional	Degree	 0.8	(1.5)	 2.3	(1.2)	P-Value	ANOVA	 0.80	 0.23	
Time	from	Onset	to	Database	Entry	
(years)	
	 	Estimate	(CI)	 0.03	(0.007-0.05)	 0.08	(0.07-0.1)	P-value	Regression		 0.01*	 <	2.2x10-16	*	
Age		 	 	Estimate	(CI)	 0.007	(-0.006-	0.02)	 0.03	(0.02-0.04)	P-value	Regression	 0.29	 1.2x10-10	*	
* Indicates a P-values less than or equal to 0.05 
 
	44 
The differences in means between the HY scores ON and OFF medication for the 
predictor and confounding variables are presented in Table 7. The time in years from the 
onset of PD symptoms to entry into the movement disorders database was positively 
associated with both HY scores ON and OFF medication.  The linear regression models 
for age and HY scores ON and OFF medication demonstrated that age was associated 
with only the on HY scores OFF medication. There was a significant difference between 
the mean HY ON and HY OFF scores between males and females, which suggests that 
sex may have an impact on disease severity in PD. Lastly, race, education and sleep 
disturbance did not show any significant difference between their mean HY ON and HY 
OFF scores. The initial analysis presented in Table 7 suggests that sleep disturbance, 
race, and education do not appear to have an impact on HY ON and HY OFF scores as 
their mean HY ON and HY OFF scores are not significantly different from one another.    
 
Differences in Mean Age and Mean Time from Onset to Database Entry 
Table 8: Difference in Means between Age and Onset to Database Entry 
Confounders		 Age	
Mean	(SD)	 Years	From	Onset	to	Database	Entry	
Mean	(SD)		
Sex:		 	 	Male		 68.2	(10.4)	 9.5	(7.0)	Female	 68.6	(11.7)	 9.5	(7.0)	P-value	t-test		 0.71	 0.99	
Race:		 	 	Caucasian		 68.5	(11.1)	 9.7*	(7.1)	African		 70.4	(10.2)	 5.7*	(4.4)	Spanish		 65.4	(6.5)	 7.3	(4.5)	Other		 63.6	(11.5)	 8.8	(6.6)	P-Value	ANOVA		 0.13	 0.03	
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Sleep	Disturbance:	 	 	Yes	 66.7	(10.5)	 10.0	(7.8)	No	 67.7	(9.1)	 8.2	(6.2)	Missing	Data		 68.7	(11.5)	 9.7	(7.1)	P-value	t-test		 0.53	 0.20	
Education:		 	 	Less	Than	High	School	 71.1	(7.6)	 6.8	(5.7)	Some	High	School/	No	Degree	 68.6	(16.1)	 11.6	(7.7)	High	School	Degree/GED	 68.6	(12.8)	 9.1	(7.7)	Associates	Degree		 62.3	(7.0)	 9.9	(7.3)	Some	College/	No	Degree	 68.7	(11.4)	 12.1	(9.0)	Bachelor’s	Degree	 66.7	(10.8)	 8.9	(7.0)	Graduate	or	Professional	Degree	 68.2	(10.2)	 9.2	(6.0)	P-Value	ANOVA	 0.47	 0.23	
Time	from	Onset	to	
Database	Entry	(years)	
	 	Estimate	(CI)	 0.34	(0.18-0.50)	 	P-value	Regression		 2.3x10-5	*	 	
Age		 	 	Estimate	(CI)	 	 0.14	(0.08-0.21)	P-value	Regression	 	 2.3x10-5	*	
* Indicates a P-value less than or equal to 0.05 
 
Table 8 shows the differences in mean age and mean time in years from the onset of PD 
symptoms to database entry for the predictor and confounding variables. Sleep 
disturbance, sex and education were not significantly different in terms of their mean age 
or in terms of their time in years from symptom onset to database entry. Time in years 
from symptom onset to database entry did, however, show a significant positive 
association with age as determined from a univariate linear regression model. Age 
showed a similar significant positive association with time from PD symptom onset to 
database entry as determined from a similar univariate linear regression model. Race was 
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also shown to have significant differences in years from symptom onset to database entry, 
as determined by a one-way ANOVA test. Further analysis of this significant result with 
a Tukey-Kramer test, indicated that only Caucasians and Africans had a significant 
difference in years from Onset to database entry. 
 
Univariate Linear Regression Models  
Table 9: Univariate Linear Regression Models Predicting HY ON Score Predictor		 Estimate	 CI		 P-Value		 R2	
Sleep	Disturbance:	 	0.33	 -0.28-0.94	 0.28	 0.0012	
Age:	 	0.007	 -0.005-0.02	 0.29	 0.0003	
Sex:		 	 	 	 -0.005	Male:	 Ref	 	 	 	Female:		 	0.009	 -0.28-0.03	 0.95	 	
Race:		 	 	 	 -0.003	Caucasian:		 Ref	 	 	 	African:		 	0.24	 -0.35-0.83	 0.50	 	Spanish		 -0.24	 -0.95-0.46	 0.50	 	Other:		 -0.34	 -1.11-0.44	 0.40	 	
Education:		 	 	 	 -0.008	Less	Than	High	School	 -0.06	 -0.83-0.70	 0.90	 	Some	High	School/	No	Degree	 	0.56	 -0.32-1.50	 0.21	 	High	School	Degree/GED	 	0.05	 -0.40-0.51	 0.83	 	Associates	Degree		 -0.44	 -1.44-0.60	 0.40	 	Some	College/	No	Degree	 	0.22	 -0.37-0.80	 0.50	 	Bachelor’s	Degree	 	0.10	 -0.32-0.51	 0.70	 	Graduate	or	Professional	Degree	 Ref	 	 	 	
Time	Until	Database	Entry	 0.028	 0.007-0.05	 0.01*	 0.02	
* Indicates a P-values less than or equal to 0.05 
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Table 10: Univatiate Linear Regression Models Predicting HY OFF Score: Predictor		 Estimate	 CI		 P-Value		 R2		
Sleep	Disturbance:	 	 	 	 -0.007	No	 Ref	 	 	 	Yes	 0.09	 -0.38-0.55	 0.72	 	
Age:	 0.033	 0.023-0.043	 1.2x10-10	*	 0.10	
Sex:		 	 	 	 0.005	Male:	 Ref	 	 	 	Female:		 0.47	 -0.68-1.62	 0.42	 	
Race:		 	 	 	 	Caucasian:		 Ref	 	 	 -0.004	African:		 -0.04	 -0.51-0.44	 0.90	 	Spanish		 -0.30	 -0.84-0.30	 0.35	 	Other:		 -0.26	 -0.88-0.36	 0.41		 	
Education:		 	 	 	 0.006	Less	Than	High	School	 0.49	 -0.1-1.09	 0.10	 	Some	High	School/	No	Degree	 0.74	 	0.05-1.4	 0.03	*	 	High	School	Degree/GED	 0.004	 -0.34-0.36	 0.98	 	Associates	Degree		 0.42	 -0.36-1.20	 0.29	 	Some	College/	No	Degree	 0.24	 -0.21-0.69	 0.29	 	Bachelor’s	Degree	 0.09	 -0.22-0.42	 0.56	 	Graduate	or	Professional	Degree	 Ref	 	 	 	
Time	Until	Database	Entry	 0.08	 0.068-0.10	 <2x10-16	*	 0.25	
* Indicates a P-values less than or equal to 0.05 
 
Table 9 shows all of the univariate linear regression models that were created to predict 
HY scores ON medication. The only significant finding from these models was the slight 
positive association found between time from symptom onset to database entry. Table 10 
shows all of the univariate linear regression models built to describe HY scores OFF 
medication. Sex, race, and sleep disturbance had no impact on HY scores ON and HY 
OFF medication. Age, however, was shown to have a significant positive association 
with HY scores OFF medication, but had no significant association with HY scores ON 
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medication. Time in years from symptom onset to database entry was also shown to have 
a significant positive association with HY scores OFF medication. This was the only 
variable that was shown to have a positive significant association with both HY scores 
ON and HY OFF medication in the univariate linear models. Finally, having some high 
school education without obtaining a high school degree was also associated with an 
increase in HY scores OFF medication. This finding will be discussed further in the 
discussion section, as the clinical significance of this finding is uncertain. 
 
Multivariate Linear Regression Models 
Table 11: Multivariate Linear Regression Model Predicting HY ON Score  Predictor		 Estimate	 CI		 P-Value	 R2	
Age:		 	0.01	 -0.003-0.025	 0.15	 	
Race:		 	 	 	 	Caucasian		 Ref	 	 	 	Black	 	0.22	 -0.41-0.85	 0.49	 	Spanish	 -0.04	 -0.80-0.73	 0.93	 	Others	 -0.07	 -1.03-0.88	 0.87	 	
Time	Until	Database	Entry		 0.03	 0.004-0.052	 0.02*	 	R2	 	 	 	 0.02	
* Indicates a P-values less than or equal to 0.05 
 
Table 11 shows the multivariate model run to predict HY scores ON medication using 
age, race, and time in years from onset until database entry. Gender and education were 
eliminated from the multivariate analysis as previous analysis indicated that gender and 
education had no significant effect on HY scores ON or OFF medication. This model 
yielded no significant results, except for time in years from onset to database entry, and 
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did not appear to effectively capture what variables were most significant in predicting 
HY scores ON medication, as indicated by the small R2 value.  
 
Table 12: Multivariate Linear Regression Predicting HY OFF Score Predictor		 Estimate	 CI		 P-Value	 R2	
Age:		 0.02	 0.01-0.03	 3.4x10-5	*	 	
Race:		 	 	 	 	Caucasian		 Ref	 	 	 	Black	 	0.46	 0.02-0.90	 0.04*	 	Spanish	 0.10	 -0.41-0.62	 0.68	 	Others	 -0.16	 -0.78-0.46	 0.61	 	
Time	Until	Database	Entry		 0.08	 0.06-0.09	 2x10-16	*	 	R2	 	 	 	 0.30	
* Indicates a P-values less than or equal to 0.05 
 
Table 12 shows the multivariate model run to predict HY scores OFF medication using 
age, race, and time in years from onset until database entry. This model showed that age, 
race and time in years until database entry were all significant in predicting HY scores 
OFF medication. The significant effect that race has on HY scores OFF medication is 
very interesting and will be discussed more thoroughly within the discussion section. The 
positive associations for both age and time in years from disease onset to database entry, 
are not surprising given the results from the previous analysis. 
 
Secondary Analysis 
The secondary analysis sought to investigate the association that NMS might have with 
HY scores ON and OFF medication. Building multivariate regression models would 
allow for the associations the NMS had on HY ON and OFF scores to be thoroughly 
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explored while allowing for previous predictors that were found to have a significant 
effect on HY scores ON and OFF medication to be effectively accounted for. Previous 
research indicated that hallucinations, autonomic dysfunction and dementia should have a 
significant impact on HY scores OFF medication. It is not well known, however, how 
these symptoms impact HY scores ON medication, making it hard to predict what 
association these variables might have with HY scores ON medication.  
 
Table 13: Race, Age, YOE, and Non-Motor Symptoms Predicting HY ON 
Predictors		 Estimate		 CI	 P-value		
Age	 0.008	 -0.006-0.024	 0.24	
Race	 	 	 	Caucasian		 	 	 	Black		 0.22	 -0.40-0.85	 0.50	Spanish		 -0.10	 -0.84-0.65	 0.79	Others	 -0.16	 1.06-0.74	 0.72	
Time	Until	Database	Entry	 0.023	 -0.001-0.048	 0.06	
NMS	 	 	 	Dementia		 0.17	 -0.25-0.61	 0.42	Autonomic	Dysfunction	 0.19	 -0.29-0.67	 0.43	Hallucinations	 0.12	 -0.29-0.54	 0.56	R2				0.016	 	 	 	
* Indicates a P-values less than or equal to 0.05 	
Table 14: Race, Age, YOE, and Non-Motor Symptoms Predicting HY OFF 
Predictors		 Estimate		 CI	 P-value		
Age	 0.018	 0.008-0.030	 0.0004	
Race	 	 	 	Caucasian		 Ref	 	 	Black		 0.46	 0.048-0.86	 0.02	Spanish		 0.04	 -0.44-0.54	 0.84	Others	 -0.26	 -0.86-0.33	 0.38	
Time	Until	Database	Entry	 0.07	 0.05-0.08	 4.1x10-13	
NMS	 	 	 	Dementia		 0.52	 0.24-0.80	 0.0003	Autonomic	Dysfunction	 0.47	 0.16-0.80	 0.003	
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Hallucinations	 0.28	 0.007-0.55	 0.04	R2				0.38	 	 	 	
* Indicates a P-values less than or equal to 0.05 
Tables 13 and 14 show the multivariate regression analysis utilizing age, race, time in 
years from onset to database entry, dementia, hallucinations, and autonomic dysfunction 
to predict HY scores ON and HY medication, respectively. None of these variables 
appeared to have a significant impact on HY scores ON medication, whereas all of these 
variables appeared to have a significant impact on HY scores OFF medication. The large 
effect that race has on HY scores OFF medication, while accounting for NMS is very 
interesting. Additionally, the model depicted in Table 14 appears to fit the data well, as 
based upon the R2 value and residual plots that were reviewed. These results will be 
examined in more detail in the discussion section.  
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Figure 1: HY ON Score vs. HY OFF Score Scatter Plot 
 
 
Figure 1 is a scatterplot of HY scores ON vs. HY scores OFF medication. This scatter 
plot has a locally weighted scatter plot smooth (LOWESS) line that is super imposed on 
top of it. The LOWESS line is a best-fit line used to show a general trend within a scatter 
plot. This scatter plot is very interesting, as it appears to show two distinct groups of 
patients; those who responded to treatment and those who did not. Further analysis is 
needed to explain why this trend is observed within the data. The implication of this 
scatter plot will be discussed in more detail in the next section of this thesis. 
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DISCUSSION 
 	 This study had several objectives: First, this study attempted to analyze the impact 
the primary predictive variables of race, sex, and sleep disturbance had on both HY ON 
and HY OFF scores. Secondly, this study sought to determine the relationship between 
the confounding variables of age, time in years from disease onset to database entry, and 
highest level of education achieved and HY ON and HY OFF scores. Thirdly, as its 
secondary outcome, this study sought to determine if the common NMS of autonomic 
dysfunction, dementia and hallucinations had an effect on either HY ON or HY OFF 
scores. Finally, HY ON and HY OFF scores were compared against each other in order to 
determine if these scores appeared to influence one another in any sort of meaningful 
way. The HY scoring system served as the primary outcome for the analysis. Half stage 
changes in the HY scale were considered clinically significant as both the values of 1.5 
and 2.5 were added to the HY scale after its founding in 1967. 
 
Race 
The data from the study revealed that the majority of patients were Caucasian and male. 
This appears to be a little bit odd at first glance as BUMC serves a very diverse patient 
population. Past literature has reported, however, that the prevalence of PD is higher in 
Caucasians and Latinos as compared to other racial groups. Therefore, it is not surprising 
to find that a large percentage of PD patients were Caucasian, however, it is surprising to 
find a low number of Spanish patients represented in the study. Furthermore, the larger 
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portion of Caucasian patients, as well as the small number of patients in the other racial 
categories, may also decrease the power of the study despite thereby resulting in a 
reduced probability of finding a difference between the HY ON and HY OFF scores in 
the different races studied when a difference truly exists. The decrease in power therefore 
limits the conclusions this study can make about the association between race and HY 
ON and OFF scores. 
 
Additionally, African patients with PD tend to present with more disease severity than 
their White patient peers. A one-way ANOVA test was used to determine if there was 
any significant difference between the mean HY ON and HY OFF scores across the 
various racial groups. The results showed no significant differences in the mean HY ON 
or HY OFF scores across racial groupings. This result is a bit surprising given the 
numerous studies that have reported that African patients tend to have greater disease 
severity as compared to their Caucasian peers. It is very possible, however, that no 
difference was found in the mean HY ON and HY OFF scores between the various racial 
groups simply because of the low numbers of subjects represented in the other racial 
groups, and thus these results should be interpreted with caution. Additionally, the 
“Other” racial category was composed of many different racial groups, making the results 
for this category uncertain because the effect of one group may mask the effects of 
others.  
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Interestingly, the multivariate linear regression model built to predict HY OFF scores 
showed that African patients were 0.46 points higher on the HY OFF scale as compared 
to Whites. This finding was statistically significant as the 95% confidence interval around 
this point estimate did not cross zero and the calculated p-value was 0.04. This result is 
not only statistically significant, but is also clinically meaningful as patients who are a 
half point higher on the HY scale have a significant difference in clinical disability and 
disease severity as compared to patients who are a half point below.  
 
The models reported in Tables 11 and 12 do not include sex or sleep disturbance within 
them. Sleep disturbance was excluded from these multivariate models as the majority of 
patients were missing sleep disturbance data. If sleep disturbance were included in this 
model the majority of patient data would not have been used in these models, which 
could greatly skew the results. Sex was excluded from this model because the student t-
test and the univariate linear regression analysis indicated that sex did not have a 
significant fact on HY ON or HY OFF scores and therefore it seemed unlikely that sex 
would influence the results within these models. In fact, when gender was included in the 
multivariate analysis (results not shown) the results of the model were not significantly 
changed.  
 
Past literature has indicated that the greater disease severity reported in African patient’s 
most likely stems from these patients having been diagnosed at a later stage of disease. 
Studies have supported this claim by reporting that African patients do not report the 
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same level of disability as their Caucasian peers, even when both patients have the same 
level of disease severity. This study, however, seems to suggest that something else may 
also be causing this observed difference in disease severity between African and 
Caucasian patients as Caucasian patients were, on average, placed into the movement 
disorders database after a longer period from initial disease onset (Table 8). This finding 
is a bit limited in that the time in years from disease onset to database entry is only a 
proxy for estimating the delay between disease onset and diagnosis; however, it is 
possible that many other factors may have caused this observed difference in disease 
severity, for example, access to care.  
 
Even though the analysis run on race and HY ON scores yielded no significant 
differences, the results are still meaningful, as they indicated that patients within the 
different racial groups has an equal response to treatment. This finding is reassuring, as it 
appears that the symptoms experienced by PD patients of different races are adequately 
addressed. The HY scale is a bit biased as it heavily relays on postural instability to 
indicate disease severity, and therefore it is possible that patients of different races have 
significant differences in the other PD motor and non-motor symptoms, which are not 
assessed by the HY scale. 
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Sex 
Past literature has indicated that men are more likely than women to develop PD, and 
therefore it is not surprising that this study’s population was comprised of more men than 
women PD patients.  
 
The difference between the means of HY OFF in both male and female patients was 
significantly different, as reported by the results of the student t-test. Interestingly, the 
results of the multivariate linear regression analysis showed no significant impact of sex 
on either HY ON or HY OFF scores. Even though the difference in HY OFF scores is 
significant between males and females, it is a very small difference of only 0.2 points on 
the HYOFF score. A 0.2 difference is not clinically meaningful because patients who 
differ by 0.2 points would be impossible to detect clinically and therefore would most 
likely be grouped into the same HY OFF score category. Furthermore, past literature 
gives no clear indication of whether males or females exhibit a true clinical difference in 
PD disease severity. 
 
When the difference between men and women in terms of their HY ON scores were 
analyzed no significant difference was found both within a multivariate linear regression 
model and within a student t-test. Again, no difference being found between the HY ON 
scores indicates that both sexes were adequately treated for the PD symptoms. Even 
though these data indicated that there was no clinically significant difference between 
males and females in terms of disease severity as measured by the HY scale, it was very 
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possible that both sexes experienced PD symptoms differently and that significant 
differences between the sexes in PD symptoms may exist. 
 
Sleep Disturbance 
As previously mentioned in the introduction, sleep disturbance is a highly prevalent 
problem with PD patients and is a widely recognized preclinical symptom of PD. Sleep 
disturbances is therefore a very interesting and relevant topic within PD research. This 
study showed that the vast majority, 68.1%, of PD patients were not asked about sleep 
disturbance during the survey. This large amount of missing data was a significant 
obstacle in analyzing the association between sleep disturbance and HY scores both in 
the ON medication and OFF medication states. Therefore, the only analysis performed on 
sleep disturbance was a simple t-test to determine whether or not the presence of sleep 
disturbance was correlated with higher HY ON and OFF scores.  
 
Interestingly, mean HY ON scores were higher, on average, than mean HY OFF scores 
for patients who both reported and who did not report sleep disturbance. This trend was 
opposite of all other data included in the study, as mean HY ON scores were typically 
lower than mean HY OFF scores. This observed trend has not been reported by other 
studies making it very interesting. The fact that the HY ON scores were higher for 
patients who both reported and did not report sleep disturbance seems to indicate that 
something other than sleep disturbance maybe responsible for this observed trend. This 
line of thinking is also supported by the fact that the student t-test did not find a 
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significant difference between mean HY ON and HY OFF score for patients who 
reported and who did not report sleep disturbance. Furthermore, this observation 
indicates that patients who report and who do not report sleep disturbance were worse on 
medication than off of it. A follow up-study should be conducted on these patients if at 
all possible to confirm this result because it seems contrary to what is expected and 
observed within PD patients.  
 
Additionally, patients who were not asked about sleep disturbance showed an average 
lower mean HY ON score as compared to mean HY OFF score, which is similar to all 
other data displayed in Table 7. Utilizing a student t-test it was shown that the difference 
between mean HY ON and OFF scores did not differ significantly for patients who 
reported sleep disturbance as well as those who did not report sleep disturbance. When 
analyzing the difference between patients who were not asked about sleep disturbance, as 
reported by the missing data value in Table 7, it was found that the difference between 
mean HY scores in both the on and off medication states was significantly different 
between patients missing data and patients who were asked about sleep disturbance. The 
results from these t-tests are not shown. It is difficult to draw conclusions from this 
analysis because it is likely that patients who were not asked about sleep disturbance 
were not a homogeneous group of individuals. The fact that a clinically significant 
difference does exist between patients who were asked about sleep disturbance and those 
who were not is interesting and should be explored further in a new study.  
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Overall, these results indicate that something peculiar is happening within PD patients 
who were asked about sleep disturbance as compared to those who were not asked about 
sleep disturbance. It was impossible, however, to explore this relationship further because 
of the small number of patients who where asked about sleep disturbance. These results 
do clearly indicate, however, that patients should be asked about sleep disturbance more 
regularly and possibly in the future another study could seek to analyze the relationship 
between sleep disturbance and HY ON and HY OFF scores more thoroughly. 
 
Confounding Analysis 
Age was shown to have a significant effect in multiple models. The univariate linear 
models constructed with age predicting HY ON or HY OFF scores showed that age only 
had a significant impact on HY OFF score. This makes sense as age is a very well know 
predictor for PD, but is not completely relevant in the ON medication state as time of 
treatment onset plays a more significant role. Even though age was seen to have a 
statistically significant effect on the HY OFF score, the effect was not clinically 
meaningful in any of the models because the largest effect shown for age indicated, that a 
ten-year increase in age impacted the HY OFF score by only 0.3 points (Tables 7 and 
10).  
 
The time from disease onset until database entry was shown to be significant in every 
model constructed to predict HY ON and OFF scores. This finding makes time from 
disease onset to database entry interesting, as it is the only variable that was observed to 
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have a significant impact on HY ON scores. Just like age, however, this effect was very 
small and ultimately not clinically meaningful. The relationship between HY scores and 
onset of disease deserves further attention in research. A prospective cohort study that 
follows patients from disease onset would be able to access this relationship more 
thoroughly, allowing for more conclusive data to be analyzed.  
 
Education was examined as a potential confounder in this study. The relationship 
between education and the severity of PD is unclear and has not been well studied. 
Education was largely insignificant in many of the multivariate linear regression models 
created and analyzed over the course of this project. The univariate linear regression 
model, Table 10, predicting HY OFF score based on education was the only model that 
showed a statistically significant result. This model showed that some high school 
education without having graduated was positively correlated with HY OFF scores. This 
finding also appears to be clinically significant as patients with some high school 
education without having graduated had a 0.74 point increase in HY OFF score as 
compared to patients who had a graduate or professional degree. The association behind 
this relationship is unclear and it is likely that many different factors played a role such as 
socioeconomic status. Future research would need to be conducted in order to determine 
what is driving this relationship. 
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Secondary Analysis The	secondary	analysis	sought	to	examine	the	association	between	several	NMS	and	how	they	relate	to	HY	ON	and	HY	OFF	scores.	These	multivariate	linear	regression	models	are	reported	in	Tables	13	and	14.	NMS	were	looked	at	in	more	detail,	as	sleep	disturbance	yielded	no	significant	results.	The	NMS	chosen	for	this	analysis	included	dementia,	autonomic	dysfunction	and	hallucinations.	Hallucinations	were	of	particular	interest	because	they	have	been	related	to	RBD.		These	models	also	included	race,	time	from	onset	until	database	entry,	and	age.	Sex	was	not	included	in	these	models	because	previous	models	examining	the	same	variables	showed	sex	to	be	insignificant.		
Table	13	shows	the	results	of	the	multivariate	linear	regression	model	predicting	HY	ON	score.	There	were	no	significant	results.	Time	in	years	until	database	entry	was	close	to	being	significant	but	was	not	quite	significant	as	indicated	by	the	95%	confidence	interval	and	the	p-value	or	0.06.	Even	if	this	result	was	statistically	significant	it	would	not	meet	the	criteria	to	be	clinically	significant,	since	the	impact	time	from	onset	to	database	entry	had	a	very	small	effect.	The	effect	of	time	in	years	from	onset	to	database	entry	was	so	small	that	patients	who	had	a	ten	year	gap	between	onset	of	PD	and	being	added	to	the	base	would	have	had	their	HY	ON	score	increased	by	0.2	points.	This	small	increase	would	not	be	detectable	at	the	clinical	level.		
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Table	14	shows	the	same	regression	model	as	Table	13	except	this	model	predicted	HY	OFF	scores.	This	model	had	several	significant	results.	Age	was	shown	to	have	a	statistically	significant	result,	and	like	previous	models	this	result	was	not	clinically	significant	due	to	the	small	value	of	the	estimate.	The	same	was	true	of	time	in	years	from	disease	onset	to	database	entry.	This	model	also	showed	that	African	patients	had	a	0.46	increase	in	HY	OFF	scores	as	compared	to	Caucasian	patients.		This	result	was	very	similar	to	the	one	depicted	in	Table	12,	except	the	result	seen	here	was	more	significant	as	evidenced	by	the	narrower	95%	confidence	interval	and	the	smaller	p-value.	Dementia,	Autonomic	dysfunction	and	hallucinations	all	had	a	statistically	significant	impact	on	HY	OFF	scores.	Dementia	had	the	most	clinically	meaningful	impact	out	of	these	three	NMS	as	patients	who	had	dementia	had	an	increase	in	HY	OFF	score	by	0.52	points.	This	result	is	both	clinically	detectable	as	the	HY	scale	is	able	to	detect	half	point	changes,	and	clinically	meaningful	as	a	half	point	increase	in	the	HY	scale	represents	a	large	change	in	PD	disease	severity.	Autonomic	dysfunction	had	the	next	most	clinically	significant	result	as	patients	with	autonomic	dysfunction	had	an	increase	of	0.47	points	in	HY	OFF	scores	as	compared	to	patients	without	autonomic	dysfunction.	Hallucinations	did	not	appear	to	have	a	clinically	significant	impact	on	HY	OFF	scores.	This	was	because	patients	who	had	hallucinations	experienced	an	increase	in	their	HY	OFF	score	of	0.28	points	on	average,	which	would	be	difficult	to	detect	in	the	clinic.	Additionally,	the	95%	confidence	interval	around	this	estimate	was	fairly	large	indicating	that	hallucinations	had	a	more	varied	effect	on	HY	OFF	score	as	compared	
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to	dementia	and	autonomic	dysfunction.	It	is	interesting	how	all	of	these	NMS	had	an	independent	effect	on	HY	OFF	score,	as	this	suggests	that	patients	with	multiple	NMS	could	have	a	drastic	increase	in	disease	severity.	Patients	have	been	reported	to	have	an	average	of	nine	NMS	making	the	individual	impact	that	these	NMS	have	on	disease	severity	an	import	aspect	of	PD	to	consider.			The	final	analysis	that	will	be	considered	in	this	section	is	depicted	in	Figure	1.	
Figure	1	is	a	scatter	plot	that	shows	HY	ON	scores	graphed	against	HY	OFF	scores.	The	orange	line	that	was	superimposed	on	this	plot	was	a	logically	weighted	scatterplot	smoothing	(LOWESS)	line.	This	line	was	essentially	a	best-fit	line	that	was	fitted	to	the	data	using	local	polynomials	then	connected	together.	This	plot	was	very	interesting	because	it	appeared	to	depict	two	separate	groups	of	patients,	those	who	responded	well	to	treatment	and	those	who	did	not.	Looking	at	the	far	left	hand	side	of	the	graph,	many	patients	who	had	high	HY	OFF	scores	also	exhibited	low	HY	ON	scores,	implying	that	these	patients	responded	well	to	medication.	At	a	HY	ON	score	of	one	the	graph	then	begins	to	show	a	linear	trend	whereby	both	HY	ON	and	HY	OFF	scores	increase	similarly.	Patients	who	fit	along	this	line	appeared	to	show	a	gradual	and	steady	increase	in	both	HY	ON	and	OFF	scores,	indicating	that	these	patients	were	beginning	to	experience	a	decrease	in	treatment	response.	It	could	be	possible	that	patients	who	were	responding	well	to	treatment	were	still	within	the	“honeymoon”	period	of	PD	treatment.	This	period	usually	lasts	for	the	first	five	years	of	treatment,	as	this	is	the	period	of	time	where	patients	have	the	most	
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effective	response	to	L-dopa	therapy.	Figure	1	shows	a	very	interesting	trend	between	HY	ON	and	HY	OFF	scores	and	future	researchers	should	more	thoroughly	investigate	this	trend	by	looking	for	possible	data	that	may	help	to	explain	this	observation.			
Limitations 
The major limitation of this study was missing data. Missing data greatly impacted the 
conclusions that could be drawn about sleep disturbance. Sleep disturbance was a very 
interesting topic with PD and has been gaining more attention in the literature over the 
years. Missing data also impacted the various linear models that were built, as missing 
data cannot be included into these models. Onset data had a significant amount of 
missing data, which could have impacted the linear models within which it was included. 
To accommodate for this problem it would be interesting to re-run all of the regression 
analysis excluding time in years from onset to database entry in order to determine what 
effect this missing data might have had on these models.  
 
Another limitation was use of the HY score. The HY score is a fast and useful method for 
classifying the disease severity observed within PD patients. The HY scale, however, is 
highly based on postural symptoms and does not account for other symptoms of PD that 
can contribute to disease severity like NMS. The use of the HY therefore limits the 
conclusions that can be drawn about the difference in disease severity observed in the 
study subjects that results from other motor symptoms like tremor, and NMS. The HY 
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scale is advantageous in that it is a widely used scale, is easily used, and is able to rank 
the severity of PD in a way that is easy to interpret.  The UPDRS, if used, could better 
account for the different aspects of PD as it is a more holistic scale by accounting for 
NMS and many of the observed motor symptoms. Using the UPDRS scale is not always 
practical, however, as it is more time consuming and harder to implement than the HY 
scale. Additionally, missing data also impacted the HY scale as 60 patients were missing 
data for HY ON and HY OFF score.  
 
The combining of racial categories was also an issue. Combining racial categories was 
necessary to increase the sample size of each racial group so that they could be compared 
statistically. In doing so, however, this may have decreased the accuracy of the results 
obtained from the analysis. The ‘Other’ racial category analyzed was most affected by 
this fact because it was comprised of patients who were from Asian decent, who were 
Native American and who originated from the pacific islands. It is clear that these racial 
groups are not at all equivalent and it is not surprising that no significant results were 
found for this group. The large percentage of Caucasian patients also greatly impacts the 
results of this study by decreasing the external validity of the study. The external validity, 
however, may not be as decreased as other studies with a similar number of Caucasian 
patients, as PD is most prevent within the Caucasian population.  
 
Finally this study shares all the same limitations as other cross sectional studies. The 
major limitation of cross-sectional study is that it is impossible to figure out whether the 
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exposure or outcome of interest came first. Therefore it is impossible to determine cause 
and affect relationships from this study. The fact that the data had been collected and de-
identified was necessary for ensuring patient confidentiality and safety, but comes at the 
price of not being able to consult medical records to collect information that might 
otherwise be missing.  
 
Overall, the movement disorders database was a valuable tool to analyze various aspects 
of PD as a wealth of information was stored within it. The movement disorders database 
therefore enabled many different questions to be asked of it. Even though these 
limitations restricted the conclusions of this study that can be applied to other 
populations, this study does accurately reflect PD patients who were receiving treatment 
at BUMC. 
 
Conclusion 
This study aimed to investigate the role sleep disturbance, sex, and race had on severity 
of PD as measured by the HY scale both in the ON and OFF medication states.  
 
 Overall this study found that males and females did have significantly different mean 
HY OFF scores, but this differences where determined to not be of clinical significance. 
Furthermore, Africans were observed to have a higher HY OFF score as compared to 
Caucasians in the multivariable linear regression model. Finally, the limited data 
collected on sleep disturbance greatly hindered the ability to draw any conclusions about 
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the correlation between sleep disturbance and HY scores. Therefore, future studies would 
have to be done at BUMC to figure out what role sleep disturbance plays in the severity 
of PD.  
 
Additionally, the secondary analysis revealed that dementia, hallucinations, and 
autonomic dysfunction all had a significant impact on HY OFF scores.  Furthermore, the 
scatter plot of HY ON and HY OFF scores indicated that some patients responded to 
treatment while others did not, which should be investigated further.   
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